rs145588689

Variant summary

Our verdict is Uncertain significance. The variant received 4 ACMG points: 5P and 1B. PS3PP5BP4

The NM_001111.5(ADAR):​c.577C>G​(p.Pro193Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00316 in 1,614,176 control chromosomes in the GnomAD database, including 6 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). ClinVar reports functional evidence for this variant: "SCV002041618: A publication also reported experimental evidence evaluating an impact on protein function, and demonstrated a partial loss of function for the variant protein (Mannion_2014)." and additional evidence is available in ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P193L) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0023 ( 1 hom., cov: 32)
Exomes 𝑓: 0.0032 ( 5 hom. )

Consequence

ADAR
NM_001111.5 missense

Scores

6
8
4

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:25U:3O:2

Conservation

PhyloP100: 8.43

Publications

85 publications found
Variant links:
Genes affected
ADAR (HGNC:225): (adenosine deaminase RNA specific) This gene encodes the enzyme responsible for RNA editing by site-specific deamination of adenosines. This enzyme destabilizes double-stranded RNA through conversion of adenosine to inosine. Mutations in this gene have been associated with dyschromatosis symmetrica hereditaria. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2010]
ADAR Gene-Disease associations (from GenCC):
  • Aicardi-Goutieres syndrome 6
    Inheritance: AD, AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • dyschromatosis symmetrica hereditaria
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • ADAR-related type 1 interferonopathy
    Inheritance: AR, AD Classification: DEFINITIVE Submitted by: ClinGen
  • Aicardi-Goutieres syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • familial infantile bilateral striatal necrosis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Leigh syndrome
    Inheritance: AR Classification: LIMITED Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 4 ACMG points.

PS3
PS3 evidence extracted from ClinVar submissions: SCV002041618: A publication also reported experimental evidence evaluating an impact on protein function, and demonstrated a partial loss of function for the variant protein (Mannion_2014).; SCV002768143: "In addition, functional studies show that this variant causes reductions in RNA editing efficiency, but only in compound heterozygote with another pathogenic variant (Mannion, N. M. et al. (2014))."; SCV000321382: knock-in mouse model for this variant supports that it could be a hypomorph variant (PMID: 34343497); SCV002064425: Functional studies in HEK293 cells transfected with the p.Pro193Ala variant exhibit a significant decrease in RNA-editing enzyme activity (Mannion et al., 2014).; SCV000742076: "In one study, functional analysis in HEK293 cells demonstrated that the p.P193A alteration results in significantly decreased RNA-editing activity compared to wildtype (Mannion, 2014)"; SCV000914349: Expression analysis of p.Pro193Ala in HEK293 cells showed a significant reduction in RNA-editing enzyme activity (Mannion et al. 2014).; SCV004105363: This variant has been reported in the compound heterozygous state in multiple families with Aicardi-Goutières syndrome and is predicted to disrupt DNA binding (Rice et al. 2012. PubMed ID: 23001123; Livingston et al. 2015. PubMed ID: 24262145; Piekutowska-Abramczuk et al. 2016. PubMed ID: 28139822).
PP5
Variant 1-154602065-G-C is Pathogenic according to our data. Variant chr1-154602065-G-C is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 126395.
BP4
Computational evidence support a benign effect (MetaRNN=0.037495464). . Strength limited to SUPPORTING due to the PP5.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_001111.5. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
ADAR
NM_001111.5
MANE Select
c.577C>Gp.Pro193Ala
missense
Exon 2 of 15NP_001102.3P55265-1
ADAR
NM_001365045.1
c.604C>Gp.Pro202Ala
missense
Exon 2 of 15NP_001351974.1
ADAR
NM_015840.4
c.577C>Gp.Pro193Ala
missense
Exon 2 of 15NP_056655.3P55265-2

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
ADAR
ENST00000368474.9
TSL:1 MANE Select
c.577C>Gp.Pro193Ala
missense
Exon 2 of 15ENSP00000357459.4P55265-1
ADAR
ENST00000368471.8
TSL:1
c.-309C>G
5_prime_UTR
Exon 2 of 15ENSP00000357456.3P55265-5
ADAR
ENST00000649724.2
c.607C>Gp.Pro203Ala
missense
Exon 2 of 15ENSP00000497932.2A0AAG2TPY2

Frequencies

GnomAD3 genomes
AF:
0.00230
AC:
350
AN:
152198
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000845
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00366
Gnomad ASJ
AF:
0.000576
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000622
Gnomad FIN
AF:
0.000376
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00357
Gnomad OTH
AF:
0.00335
GnomAD2 exomes
AF:
0.00221
AC:
555
AN:
251460
AF XY:
0.00229
show subpopulations
Gnomad AFR exome
AF:
0.000800
Gnomad AMR exome
AF:
0.00260
Gnomad ASJ exome
AF:
0.000397
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000878
Gnomad NFE exome
AF:
0.00338
Gnomad OTH exome
AF:
0.00130
GnomAD4 exome
AF:
0.00325
AC:
4748
AN:
1461860
Hom.:
5
Cov.:
89
AF XY:
0.00314
AC XY:
2284
AN XY:
727232
show subpopulations
African (AFR)
AF:
0.000538
AC:
18
AN:
33480
American (AMR)
AF:
0.00304
AC:
136
AN:
44720
Ashkenazi Jewish (ASJ)
AF:
0.000230
AC:
6
AN:
26134
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39696
South Asian (SAS)
AF:
0.000951
AC:
82
AN:
86248
European-Finnish (FIN)
AF:
0.000786
AC:
42
AN:
53420
Middle Eastern (MID)
AF:
0.000173
AC:
1
AN:
5768
European-Non Finnish (NFE)
AF:
0.00388
AC:
4310
AN:
1112000
Other (OTH)
AF:
0.00253
AC:
153
AN:
60394
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.482
Heterozygous variant carriers
0
344
689
1033
1378
1722
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
162
324
486
648
810
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00230
AC:
351
AN:
152316
Hom.:
1
Cov.:
32
AF XY:
0.00209
AC XY:
156
AN XY:
74480
show subpopulations
African (AFR)
AF:
0.000842
AC:
35
AN:
41566
American (AMR)
AF:
0.00366
AC:
56
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
0.000576
AC:
2
AN:
3472
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5192
South Asian (SAS)
AF:
0.000622
AC:
3
AN:
4822
European-Finnish (FIN)
AF:
0.000376
AC:
4
AN:
10628
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00357
AC:
243
AN:
68016
Other (OTH)
AF:
0.00379
AC:
8
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
20
40
61
81
101
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00183
Hom.:
0
Bravo
AF:
0.00251
TwinsUK
AF:
0.00270
AC:
10
ALSPAC
AF:
0.00545
AC:
21
ESP6500AA
AF:
0.00204
AC:
9
ESP6500EA
AF:
0.00372
AC:
32
ExAC
AF:
0.00214
AC:
260
Asia WGS
AF:
0.000577
AC:
2
AN:
3478
EpiCase
AF:
0.00349
EpiControl
AF:
0.00391

ClinVar

ClinVar submissions
Significance:Conflicting classifications of pathogenicity
Revision:criteria provided, conflicting classifications
View on ClinVar
Pathogenic
VUS
Benign
Condition
10
-
-
Aicardi-Goutieres syndrome 6 (11)
7
-
-
not provided (7)
1
2
-
Symmetrical dyschromatosis of extremities (3)
2
1
-
Symmetrical dyschromatosis of extremities;C3539013:Aicardi-Goutieres syndrome 6 (4)
2
-
-
ADAR-related disorder (2)
1
-
-
ADAR-related type 1 interferonopathy (1)
1
-
-
Aicardi Goutieres syndrome (1)
1
-
-
Inborn genetic diseases (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.31
BayesDel_addAF
Uncertain
0.029
T
BayesDel_noAF
Pathogenic
0.27
CADD
Uncertain
24
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.68
D
Eigen
Pathogenic
0.75
Eigen_PC
Uncertain
0.65
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.87
D
M_CAP
Uncertain
0.19
D
MetaRNN
Benign
0.037
T
MetaSVM
Uncertain
0.18
D
MutationAssessor
Benign
1.9
L
PhyloP100
8.4
PrimateAI
Benign
0.38
T
PROVEAN
Uncertain
-3.0
D
REVEL
Pathogenic
0.74
Sift
Pathogenic
0.0
D
Sift4G
Pathogenic
0.0
D
Polyphen
1.0
D
Vest4
0.57
MVP
0.85
MPC
0.87
ClinPred
0.041
T
GERP RS
4.5
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.96
gMVP
0.58
Mutation Taster
=72/28
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs145588689; hg19: chr1-154574541; COSMIC: COSV105112956; COSMIC: COSV105112956; API
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.